Regulators Wonder if Cancer Patients ‘Need’ New Treatments

Matthew D. Mitchell and Anna Parsons write on regulatory hurdles faced in introducing a new cancer drug, despite the drug already having been approved by the FDA.

Read it at the Wall Street Journal.